These statements have not been evaluated by the FDA
While not specifically associated with semaglutide, any concerning skin changes warrant dermatologic evaluation
In REDEFINE 1 (overweight/obesity without T2D), CagriSema achieved mean weight reductions of 20.4-22.7% (vs 2.3-3.0% placebo) at 68 weeks, with 53.6% and 34.7% of patients achieving 20% and 25% weight loss, respectively
Download the PeptIQ app to track your retatrutide journey, log dosing and side effects, monitor weight and body composition changes, and connect with others optimizing their metabolic health
That is going to be your best chance at maintaining your thyroid function for the rest of your life
We have extensive experience fighting for patients who think they have been harmed by pharmaceutical drugs, like Ozempic